Navigation Links
Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System

Key words: AMARA • kinase assay • LEADseeker • chemiluminescence


It is predicted that at least 500 kinase and phosphatase enzymes exist, their activities having wide-ranging regulatory responses. Many kinases are part of a signaling cascade in disease pathways such as inflammation and cancer, so identifying modulators of kinase and phosphatase activity may provide new therapeutic agents.

This application note provides recommendations for the successful imaging of the AMARA HitHunter™ Chemiluminescence Kinase Assay on the LEADseeker™ Multimodality Imaging System and demonstrates the assay’s ability to measure the functional activity of serine/threonine kinase AMP in the phosphorylation of the AMARA substrate (AMARAASAAALARRR).


Materials
Reagents and instrumentation

AMARA HitHunter Chemiluminescence 90-0060-02
Kinase Assay Kit*, 800 (384 wells)

LEADseeker Multimodality Imaging System 18-1140-71

[14C] Uniform Reference Plate CFQ11387-4UCI


Additional materials required
AMP-activated protein kinase (Upstate #14-305)

ATP (Sigma A-7699)

Adenosine monophosphate (AMP) (Sigma A-2002)

384-well white flat bottom polystyrene (Corning 3705)
not treated microplates

Graphpad Prism software v.4 (GraphPad Software)


Method
LEADseeker setup
A flat field correction was established using a [14C] Uniform Reference Plate. No background correction was required.

Plates were imaged on the LEADseeker Multimodality Imaging System for 60 s with coincident averaging and 3 × 3 binning.

Reagent preparation
1. The kinase enzyme was diluted using the antibody reagent supplied in the kit to give a range of working stocks yielding a final concentration range in the assay from 0.05 to 100 units/well.

2. The AMARA substrate and ATP were diluted with the assay buffer supplied in the kit to yield working stocks of 20-µM AMARA substrate, 40-µM ATP, and 400-µM AMP.

3. The chemiluminescent substrate (CLS) was prepared by mixing 1 part Galacton-Star™, 5 parts Emerald-II™, and 19 parts CLS diluent.

4. The enzyme donor (ED)/CLS mix was prepared by carefully mixing 1 part ED reagent with 1 part CLS and was used within 6 h.

5. The enzyme acceptor (EA) reagent was used as supplied.

Assay procedure

1. To the kinase assay wells, add 10 µl of kinase reaction buffer to each well. To the standard curve wells, add 10 µl of AMARA standard and 10 µl of AMARA antibody reagent.

2. Incubate plate in darkness for 60 min at room temperature (20–25 ºC).

3. Add 20 µl of ED/CLS to each well.

4. Incubate plate in darkness for 60 min (± 15 min) at room temperature.

5. Add 10 µl of EA reagent to each well.

6. Incubate plate in darkness at room temperature for at least 60 min or overnight.

7. Seal plate and image on the LEADseeker Multimodality Imaging System for between 10 and 60 s.

Preparation of standard curve
The standard curve was established by preparing twelve 3-fold serial dilutions (using assay buffer) of the phosphorylated AMARA standard supplied in the kit. The final concentration range of the standard curve was 5.6 × 10-11 to 1.0 × 10-5 M in a final volume of 20 µl/well. Each standard concentration was assayed in triplicate.

AMP kinase titration procedure
AMP kinase was diluted in antibody reagent to yield a final concentration range of 0.05 to 100 mU/well. Each test point was assayed in triplicate. The AMARA substrate was used at a final concentration of 10 µM; ATP was used at a final concentration of 20 µM and AMP at 200 µM. The reaction was incubated for 60 min at room temperature. Following incubation with the detection reagents, the reaction was imaged on the LEADseeker Multimodality Imaging system for 60 s.


Conclusion
The AMARA HitHunter Chemiluminescence Kinase Assay has been successfully used on the LEADseeker Multimodality Imaging System and is suitable for measuring the phosphorylation of AMARA substrate by serine/threonine kinase AMP.


* The assay buffer may require supplementation with cofactors, which will be enzyme specific. This application note describes how the AMARA HitHunter™ Chemiluminescence Kinase Assay performs with serine/threonine kinase AMP; no additional cofactors were added to the assay buffer for this enzyme; however, there is a 3-fold increase in activation of the enzyme in the presence of adenosine 5’-monop hosphate (AMP).

† Other pack sizes available, please inquire for details.



back to top
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase
2. Comparing Fidelity and Performance of Proofreading PCR Enzymes
3. PCR Performance Comparisons Between pfuturbo and Taq DNA Polymerases
4. pfuturbo DNA Polymerase: A High-Performance, High-Fidelity Enzyme Ideal for PCR Cloning
5. Performance Comparisons of Commercial RT-PCR Systems
6. Restriction Endonucleases Undergo Rigorous QC Testing to Ensure Optimal Performance
7. Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR Performance
8. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
9. Challenge the Performance of Your Hot-Start PCRs with FastStart Taq DNA Polymerase and the Novel FastStart High Fidelity PCR System
10. Highly Sensitive microRNA Array Performance
11. High Throughput RNA Isolation for High Performance Microarray Analysis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... 2016 --> ... "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces ... trachomatis (CT) test to be launched on the Company,s io® ... the CT test is now cleared for sale within the ... The launch of the io® CT test signals a new ...
(Date:2/5/2016)... , Feb. 5, 2016 On Thursday, ... trusted information source for community, health and disaster services, ... will integrate to enhance care coordination and service ... the services they need and to better connect service ... care.   San Diego has ...
(Date:2/4/2016)... 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... Edward Lanphier , Sangamo,s president and chief executive ... Sangamo,s ZFP Therapeutic ® development programs and an ... ET on Thursday, February 11, 2016, at the Leerink ... conference is being held in New York ...
(Date:2/4/2016)... British Columbia and MENLO PARK, Calif. ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... today announced that it will present at the 18 ... Monday, February 8, 2016 at 10:00 a.m. EST in ... Bacha , DelMar,s president and CEO, will provide an update ...
Breaking Biology Technology:
(Date:2/3/2016)... GOTHENBURG, Sweden , February 4, 2016 ... Revenues amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth ... Operating profit amounted to SEK 517.6 M (loss: 30.0). Earnings ... from operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
Breaking Biology News(10 mins):